secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-020786
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic Q1 net loss $15.6M; cash $57.4M; PKU program gets FDA/EMA designations
-------------------------------------------------------------------------------

- Net loss of $15.6M ($0.23 per share) vs $15.7M in Q1 2022; revenue flat at $0.2M.
- Cash, equivalents and short-term investments $57.4M; runway into H2 2024.
- FDA granted Rare Pediatric and Orphan Drug Designations for SYNB1934 in PKU; EMA also granted orphan designation.
- Phase 3 trial (Synpheny-3) for SYNB1934 in PKU on track to start H1 2023.
- SYNB1353 for HCU advancing to Phase 2; preclinical pipeline progressing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000095017023020786/0000950170-23-020786-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000095017023020786/sybx-20230511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-020786

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer